1Service de Neurochirurgie, CHU Cavale Blanche, INSERM UMR 1101 LaTIM, Brest.
2Service de Radiologie, CHU Cavale Blanche, INSERM EA 3878 GETBO, Brest, France.
J Neurosurg. 2018 Jun;128(6):1823-1829. doi: 10.3171/2017.2.JNS162751. Epub 2017 Sep 1.
OBJECTIVE The management of brain arteriovenous malformations (bAVMs) remains controversial. The Treatment of Brain AVMs Study (TOBAS) was designed to manage patients with bAVMs within a clinical research framework. The objective of this study was to study trial feasibility, recruitment rates, patient allocation to the various management groups, and compliance with treatment allocation. METHODS TOBAS combines two randomized care trials (RCTs) and a registry. Designed to be all-inclusive, the study offers randomized allocation of interventional versus conservative management to patients eligible for both options (first RCT), a second RCT testing the role of preembolization as an adjunct to surgery or radiotherapy, and a registry of patients managed using clinical judgment alone. The primary outcome of the first RCT is death from any cause or disabling stroke (modified Rankin Scale score > 2) at 10 years. A pilot phase was initiated at one center to test study feasibility, record the number and characteristics of patients enrolled in the RCTs, and estimate the frequency of crossovers. RESULTS All patients discussed at the multidisciplinary bAVM committee between June 2014 and June 2016 (n = 107) were recruited into the study; 46 in the randomized trials (23 in the first RCT with 21 unruptured bAVMs, 40 in the second RCT with 17 unruptured bAVMs, and 17 in both RCTs), and 61 patients in the registry. Three patients crossed over from surgery to observation (first RCT). CONCLUSIONS Clinical research was successfully integrated with normal practice using TOBAS. Recruitment rates in a single center are encouraging. Whether the trial will provide meaningful results depends on the recruitment of a sufficient number of participating centers. Clinical trial registration no.: NCT02098252 (clinicaltrials.gov).
目的 脑动静脉畸形(bAVM)的治疗仍存在争议。脑动静脉畸形治疗研究(TOBAS)旨在临床研究框架内管理 bAVM 患者。本研究的目的是研究试验的可行性、招募率、患者在各种治疗组中的分配以及对治疗分配的依从性。
方法 TOBAS 将两项随机对照试验(RCT)和一个登记处结合在一起。该研究旨在全面纳入所有符合条件的患者,对有介入和保守治疗选择的患者进行随机分配,一项 RCT 测试栓塞作为手术或放射治疗辅助的作用,另一项 RCT 测试预栓塞在治疗未破裂 bAVM 中的作用,登记处则是单独根据临床判断治疗的患者。第一项 RCT 的主要结局是 10 年内任何原因导致的死亡或致残性卒中(改良 Rankin 量表评分>2)。在一个中心启动了一个试点阶段,以测试研究的可行性,记录纳入 RCT 的患者数量和特征,并估计交叉的频率。
结果 2014 年 6 月至 2016 年 6 月,多学科 bAVM 委员会讨论的所有患者(n=107)均被纳入研究;46 例患者被纳入随机试验(第一项 RCT 中 23 例未破裂 bAVM,21 例接受保守治疗,21 例接受介入治疗;第二项 RCT 中 17 例未破裂 bAVM,40 例接受手术或放疗,17 例同时接受两项 RCT),61 例患者被纳入登记处。3 例患者从手术转为观察(第一项 RCT)。
结论 使用 TOBAS 成功地将临床研究与常规实践相结合。单中心的招募率令人鼓舞。试验是否能提供有意义的结果取决于能否招募足够数量的参与中心。临床试验注册号:NCT02098252(clinicaltrials.gov)。